Drug maker Merck  Co is facing criticism that it is overpaying for its planned  billion purchase of antibiotics specialistCubist Pharmaceuticals Inc in light of a court ruling issued hours after the deal was announced Monday that could dampen the sales potential for Cubists topselling drug Leerink Partners analyst Seamus Fernandez said the purchase price appeared to be about  billion to  billion too high based on reduced sales expectations for the Cubist drug the antibiotic Cubicin